Pediatrix Medical : Reconciliation of Forward-Looking Adjusted EBITDA Range FY 2026

Published: 2026-05-05 06:29:09 ET MD

Published on 05/05/2026 at 06:29 am EDT

PEDIATRIX MEDICAL GROUP, INC. RECONCILIATION OF NET INCOME

TO FORWARD-LOOKING ADJUSTED EBITDA

(in thousands) (Unaudited)

Year Ended

December 31, 2026

Net Income

152,100

166,700

Interest expense

33,500

Income tax expense

56,300

61,700

Depreciation and amortization expense

24,800

Transformational and restructuring related expenses

13,300

Adjusted EBITDA

$ 280,000

$ 300,000

This reconciliation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on assumptions and assessments made by Pediatrix management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements in this reconciliation are made as of May 5, 2026 and Pediatrix undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in Pediatrix's most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled "Risk Factors", as well Pediatrix's current reports on Form 8-K, filed with the Securities and Exchange Commission.

Disclaimer

Pediatrix Medical Group Inc. published this content on May 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 05, 2026 at 10:28 UTC.